List of items of drug prices and breach of trust proposed by the National Health Insurance Administration

, June 9th, the State Administration of Health Security to the China Chemical and Pharmaceutical Industry Association, China Price Association, China NarcoticDrugs Association, China Foreign Investment Enterprise Association, China Medical Device Industry Association and other 11 pharmaceutical-related industry associations (academic) will send a letter on the establishment of pharmaceutical prices and recruitment credit evaluation system guidance (draft for comments) (hereinafter referred to as draft)This is the second time the National Health Insurance Administration has sought advice on the establishment of pharmaceutical prices and credit evaluationThe draft for comments puts forward the establishment of a list of pharmaceutical prices and credit-loss matters, the development of the credit rating of pharmaceutical enterprises, the classification of the disposal of breach of trustThe specific contents of the list include, but are not limited to, pharmaceutical commercial bribery, abuse of market dominance, manipulation of market prices, violation of contractual agreements, disturbing the order of procurement and other illegal acts, contrary to good faith and fair competitionThe draft clearly states that pharmaceutical enterprises (including pharmaceutical and medical supplies production enterprises, distribution enterprises, the same below) in the pricing, bidding, performance, marketing and other processes, through the list of list of acts to engage in unfair competition, obtain improper benefits, will be included in the pharmaceutical price and tender procurement credit evaluation scopeThe implementation of the active commitment system
draft for comments, the implementation of pharmaceutical enterprises active commitment systemPharmaceutical enterprises participating in or entrusting them to participate in the centralized procurement of medicines and medical supplies, platform hanging network, and medical insurance fixed-point medical institutions (hereinafter referred to as medical institutions) to carry out the record procurement, should submit a written commitment to the drug and medical supplies centralized procurement agencies (hereinafter referred to as centralized procurement agencies), commitments include non-occurrence of list editing list of breach of trust, its employment personnel, entrustedagents
enterprisesfor their own drug implementation of the breach of trust; Pharmaceutical enterprises that have not submitted their commitments will not accept their medicines or medical supplies from the internet, tenders, or othermeaning to the medical institutionsFrom the date of formal implementation of the guidance, we will adopt a combination of enterprise reports and platform records, collect timely, comprehensive, complete and standardized information on the behavior of pharmaceutical enterprises, and establish a medical enterprise price information base for breach of trustThe centralized purchasing agency regularly combs and summarizes the judgment documents and administrative penalty decisions made by the relevant departments, collects and verifies the information of the medical enterprises and records themIn the daily operation of centralized purchasing institutions, through monitoring, correspondence, interviews and other means, grasp the information of the drug enterprise pricing, bidding, performance and other aspects of breach of trust and recordIn addition to the quarterly dynamic update, will also be in accordance with the "reliable sources, clear conditions, strict procedures, strict operation" requirements, according to the nature of the breach of trust, circumstances, timeliness, and the scope of influence and other factors, pharmaceutical enterprises in the local bidding procurement market of the breach of trust as general, medium, serious, particularly serious four grades, quarterly dynamic updates For acts of breach of trust such as commercial bribery of pharmaceutical saparations, the facts on which the credit rating is based shall be governed by the court's decision or the administrative punishment decision of the law enforcement department 　　In accordance with the credit rating of the pharmaceutical enterprise, the centralized purchasing institution shall adopt written reminders and warnings, prompt the purchaser of risk information, suspend the bidding network of the enterprise-related drugs or medical supplies, suspend the qualification of the enterprise for the distribution of the winning drugs or medical supplies, and disclose the information of the breach of trust to the public, and compact the liability for breach of trust of the pharmaceutical enterprise 　　The draft also encourages pharmaceutical companies to repair credit If the breach of trust exceeds a certain period of time, it shall no longer be retroactively included in the scope of credit evaluation and will be automatically repaired Encourage pharmaceutical enterprises to take the initiative to repair credit, remind pharmaceutical enterprises before the disposal measures take effect, and give a certain rectification period, as the circumstances, accept that they take practical measures to repair credit during the rectification period, including the termination of related breach of trust, submit compliance rectification reports, publicly issue an apology statement to eliminate adverse effects, remove the false high space in the price of drugs or medical supplies involved, return unreasonable income, etc 　　The draft also requires all localities to promote the construction and implementation of the system of pharmaceutical prices and credit evaluation, and shall not, in the name of pharmaceutical prices and credit evaluation system, intervene in the legitimate marketing and price of pharmaceutical enterprises by administrative means, and shall not adopt local protection and undermine fair competition 　　On the same day, the State Medical Insurance Administration also sent a letter to the 11 associations (studies) for comments on the "Regulations on the Operation of Pharmaceutical Prices and Credit Evaluation of Recruitment" 　　Guidance on the establishment of a system for the evaluation of pharmaceutical prices and recruitment (second draft for comments) the medical security bureaus of the provinces, autonomous regions, municipalities directly under the Central Government and Xinjiang Production and Construction Corps: commercial bribery in the field of medicine, market manipulation and other acts resulting in inflated prices of pharmaceutical and medical supplies, excessive growth of medical expenses, a large loss of medical insurance funds, seriously endangering the safety of medical insurance funds In order to implement the Opinions of the CPC Central Committee and the State Council on Deepening the Reform of the Medical Security System (Cpc (2020) No 5), improve the mechanism for the formation of market-led pharmaceutical prices, and establish a credit evaluation system for pharmaceutical prices and recruitment, the following comments are put forward 　　1 The guiding ideology based on the equal civil rights and obligations relationship between suppliers, purchasers and purchasing organizations of pharmaceutical and medical supplies, relying on the bidding and procurement platform for pharmaceuticaland medical supplies, system integration and trustworthiness commitment, credit rating, graded disposal, credit repair and other mechanisms, the establishment of equal rights and responsibilities, coordination of joint pharmaceutical prices and bidding and procurement credit evaluation system, to promote honesty and trustworthiness, and jointly create a fair and safe sense of security, clean air and clean the circulation of the public 　　2 Establish a list of credit evaluation catalogues
establish a list of pharmaceutical prices and breach of trust matters, including but not limited to pharmaceutical commercial bribery, abuse of market dominance, manipulation of market prices, violation of contractual agreements, disturbing procurement order and other illegal acts, contrary to good faith and fair competition From the date of the issuance of this Opinion, pharmaceutical enterprises (including pharmaceutical and medical supplies production enterprises, distribution enterprises, the same below) in the pricing, bidding, performance, marketing and other processes, through the list of catalogues to engage in unfair competition, obtain improper benefits, will be included in the pharmaceutical price and tender procurement credit evaluation scope 　　3 The voluntary commitment system of pharmaceutical enterprises pharmaceutical enterprises to participate in or entrust to participate in the centralized procurement of pharmaceutical and medical supplies, platform network, as well as medical insurance fixed-point medical institutions (hereinafter referred to as "medical institutions") for the record procurement, should be pharmaceutical and medical supplies centralized procurement agencies (hereinafter referred to as "centralized procurement agencies") to submit written commitments, commitments include non-occurrence of the list of breach of trust, its employees, entrusted to the agent enterprises for the implementation of their own drug breach; Pharmaceutical enterprises that have not submitted their commitments will not accept their medicines or medical supplies from the internet, tenders, or othermeaning to the medical institutions 　　Fourth, the establishment of the report ingnet report ingnet records channel
from the date of implementation of this opinion, the combination of enterprise reports and platform records, timely, comprehensive, complete and standardized collection of information on the behavior of pharmaceutical enterprises, the establishment of pharmaceutical enterprises price recruitment information base Pharmaceutical enterprises take the initiative to report the information of the breach of trust to the centralized purchasing organization where the breach of trust occurred in a timely manner The centralized purchasing agency regularly combs and summarizes the judgment documents and administrative penalty decisions made by the relevant departments, collects and verifies the information of the medical enterprises and records them In the daily operation of centralized purchasing institutions, through monitoring, correspondence, interviews and other means, grasp the information of the drug enterprise pricing, bidding, performance and other aspects of breach of trust and record 　　V To carry out the credit rating of pharmaceutical enterprises in accordance with the requirements of "reliable sources, clear conditions, strict procedures, strict operation", according to the nature of the breach of trust, circumstances, timeliness, and the scope of influence and other factors, the pharmaceutical enterprises in the local tender procurement market to assess the breach of trust as general, medium, serious, particularly serious four grades, dynamic updates on a quarterly basis For acts of breach of trust such as commercial bribery of pharmaceutical saparations, the facts on which the credit rating is based shall be governed by the court's decision or the administrative punishment decision of the law enforcement department Encourage local areas to explore quantitative credit rating methods and continuously improve the standardization of credit ratings 　　6 The graded disposal of breach of trust centralized purchasing institutions, in accordance with the credit rating of pharmaceutical enterprises, respectively, take written reminders and warnings, prompt the purchaser of risk information, suspend the enterprise-related drug or medical supplies bidding network, suspend the enterprise's distribution of winning drugs or medical supplies qualification, public disclosure of false information and other disposal measures, compacted pharmaceutical enterprise snot in breach of trust liability If the supply structure of drugs or medical supplies is single and the supply and demand situation is tight, the measures of graded disposal should be taken to take into account accessibility, so as to avoid the absence of clinical treatment methods and seriously affect the treatment of patients 　　Encourage pharmaceutical enterprises to repair credit establish a mechanism for automatic credit repair and active repair of credit enterprises If the breach of trust exceeds a certain period of time, it shall no longer be retroactively included in the scope of credit evaluation and will be automatically repaired Encourage pharmaceutical enterprises to take the initiative to repair credit, remind pharmaceutical enterprises before the disposal measures take effect, and give a certain rectification period, as the circumstances, accept that they take practical measures to repair credit during the rectification period, including the termination of related breach of trust, submit compliance rectification reports, publicly issue an apology statement to eliminate adverse effects, remove the false high space in the price of drugs or medical supplies involved, return unreasonable income, etc 　　8 The correct use of the credit evaluation system promote the construction and implementation of the system of pharmaceutical prices and credit evaluation in all places, we should adhere to laws and regulations as the criterion, market mechanism-oriented, civil rights and obligations as the fundamental, to protect the pharmaceutical enterprises enjoy the right to independent pricing and independent operation in accordance with the law; 　　To jointly promote the construction of credit evaluation system
establishing a credit evaluation system for pharmaceutical prices and recruitment is an important measure to purify the order of the pharmaceutical market, optimize the environment for pharmaceutical business, and promote the high-quality development of the pharmaceutical industry We should adhere to the principle of sharing common governance, promote the active participation of pharmaceutical enterprises and medical institutions, guide pharmaceutical enterprises to conscientiously fulfill their obligations to comply with price rules and operate in good faith, and guide medical institutions to choose pharmaceutical enterprises with better credit ratings as supply or distribution units under the same conditions The centralized purchasing institutions should further promote standardized construction, improve bidding and procurement services, make full use of information-based means to provide convenient and efficient services and support for pharmaceutical enterprises to submit commitments, record information, repair credit, etc